Boehringer Ingelheim Korea releases telmisartan and hydrochlorothiazide combination drug
The combination drug is indicated for the treatment of mild to moderate hypertension in patients that have failed to achieve the desired antihypertensive effect through monothera...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
